Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback